## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

18 March, 2015

#### Name of entity

Altech Chemicals Limited

**ABN** 

45 125 301 206

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- <sup>+</sup>Class of <sup>+</sup>securities issued or to be issued
- (a) Ordinary shares
- (b) Options (Ex price \$0.10 Exp. 15 Dec. 2015)
- (c) Performance rights
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- (a) 250,000 ordinary shares
- (b) 250,000 options
- (c) 5,250,000 performance rights
- Principal terms of the 3 +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due payment: dates for if +convertible securities, the conversion price and dates for conversion)
- (a) Ordinary shares rank pari passu with existing ordinary shares.
- (b) Options are exercisable at \$0.10 each, are quoted and expire 5pm 15 December 2015. Ordinary shares issued from the exercise of options will rank pari passu with existing ordinary shares.
- (c) Performance Rights are not quoted, are exercisable at Nil consideration and ordinary shares issued from the exercise of performance rights will rank pari passu with existing ordinary shares.

+ See chapter 19 for defined terms.

01/08/2012 Appendix 3B Page 1

4 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- (a) Ordinary shares rank pari passu with existing ordinary shares.
- (b) Options will be quoted and upon exercise the issued ordinary shares will rank pari passu with existing ordinary shares.
- (c) Performance Rights will not be quoted and upon exercise the issued ordinary shares will rank pari passu with existing ordinary shares.

- 5 Issue price or consideration
- (a) Ordinary shares: \$0.10 per share.
- (b) Options are issued for nil consideration.
- (c) Performance Rights are issued for nil consideration.
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

To provide funds to enable the Company to complete a Bankable Feasibility Study into the development of a High Purity Alumina (HPA) processing plant and for corporate and general working capital purposes.

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in relation to the* +securities the subject of this Appendix 3B, and comply with section 6i

The date the security holder resolution | 5 November 2014

under rule 7.1A was passed

6c Number of \*securities issued without security holder approval under rule 7.1

(a) Ordinary shares: Nil

(b) Options: Nil

(c) Performance Rights: Nil

6d Number of \*securities issued with security holder approval under rule 7.1A

nil

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	n/a	
6f	Number of securities issued under an exception in rule 7.2	(a) Ordinary Shares: 2 (b) Options: 250,000 (c) Performance Right	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	n/a	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	n/a	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 16,764,468 7.1A: 11,176,312	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	18 March 2015	
		N. 1	+ 01
8	Number and *class of all *securities	Number 112,013,117	+Class Ordinary Shares
Ü	quoted on ASX (including the securities in section 2 if applicable)	21,465,000	Options (exercise price \$0.20, expiring 31 May 2015)
		4,027,735	Options (exercise price \$0.10, expiring 15 December 2015)

o1/08/2012 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the securities in section 2 if applicable)

Number	+Class
8,000,000	Ex. \$0.20, Expiry 31-05-2015
1,000,000	Ex. \$0.20, Expiry 18-12-2017
1,000,000	Ex. \$0.25, Expiry 18-12-2017
1,000,000	Ex. \$0.30, Expiry 18-12-2017
200,000	Ex. \$0.25, Expiry 15-09-2015
600,000	Ex. \$0.20, Expiry 31-01-2017
157,700	Performance Rights: Employees
15,000,000	Performance Rights: Managing
	Director
5,250,000	Performance Rights: Directors

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

n/a			

## Part 2 - Bonus issue or pro rata issue

11	is security noider approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	*Class of *securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	

19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

o1/08/2012 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

32	How do *security holders dispose of their entitlements (except by sathrough a broker)?	
33	<sup>+</sup> Despatch date	
	t 3 - Quotation ad only complete this section if you are appl	
34	Type of securities (tick one)	
(a)	✓ Securities described in Part 1 (	Note: (a) Shares and (b) Options)
(b)	*	of the escrowed period, partly paid securities that become fully paid, restriction ends, securities issued on expiry or conversion of convertible
Ent <sup>-</sup>	ities that have tic	ked box 34(a)
Additi	ional securities forming a new c	lass of securities
Tick to docume	indicate you are providing the information	n or
35	1 1	ecurities, the names of the 20 largest holders of the 20 number and percentage of additional *securities
36	1 1	ecurities, a distribution schedule of the additional aber of holders in the categories
37	A copy of any trust deed for th	e additional <sup>+</sup> securities

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

## Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	<sup>+</sup> Class

oı/o8/2012 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: \_\_\_\_\_ Date: 18 March 2015 (Director/Company Secretary)

Print name: Shane Volk

== == == ==

Appendix 3B Page 8 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	107,758,502	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	3,777,735 (Entitlement offer 12/14) 226,880 (Exercise of Employee Rights 2/12)	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	Nil	
Number of partly paid ordinary securities that became fully paid in that 12 month period	Nil	
<ul> <li>Note:</li> <li>Include only ordinary securities here — other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	111,763,117	

01/08/2012 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	16,764,468	
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
Under an exception in rule 7.2		
• Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	16,764,468	
Note: number must be same as shown in Step 2		
Subtract "C"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	16,764,468	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	111,763,117	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	11,176,312	
Insert number of equity securities issued or	Nil	
agreed to be issued in that 12 month period under rule 7.1A		

01/08/2012 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	11,176,312	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	11,176,312	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.